<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492242</url>
  </required_header>
  <id_info>
    <org_study_id>CIC1421-18-06</org_study_id>
    <nct_id>NCT03492242</nct_id>
  </id_info>
  <brief_title>Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction</brief_title>
  <acronym>CHIMeRA</acronym>
  <official_title>Monitoring of Immune Checkpoint Inhibitors Adverse Drug Reactions Through the WHO Vigilyze and French Pharmaco-vigilance Database (Base Nationale de Pharmacovigilance BNPV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events
      (irAEs) from rhumatologic, endocrinologic, cardiac or other system origin. This study
      investigates reports of drug induced irAEs with treatment including anti-PD1, Anti-PDL-1, and
      Anti-CTLA4 classes using the World Health Organization (WHO) database VigiBase and the french
      database Base Nationale de PharmacoVigilance (BNPV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immune checkpoint inhibitors (ICIs) have dramatically improved clinical outcomes in multiple
      cancer types and are increasingly being tested in earlier disease settings and used in
      combination. However, immune-related adverse events (irAEs) can occur. Here the investigators
      use VigiBase (http://www.vigiaccess.org/), the World Health Organization (WHO) database of
      individual safety case reports, and in the Base Nationale de PharmacoVigilance (BNPV) which
      is the french pharmacovigilance database, to identify cases of adverse drug reaction
      including arthiritis, auto-immune induced diseases, cardiac diseases, endocrinologic
      diseases, following treatment with ICIs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse drug reactions induced by ICIs and reported in the World Health Organization (WHO) or the Base Nationale de Pharmacovigilance (BNPV)</measure>
    <time_frame>Case reported in the World Health Organization (WHO) or BNPV database of individual safety case reports to May 2018</time_frame>
    <description>Identification and report of cases of adverse events associated with ICIs. Drugs investigated are ICIs: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Causality assessment of reported adverse drug reaction according to the WHO system</measure>
    <time_frame>Case reported in the World Health Organization (WHO) or BNPV database of individual safety case reports to May 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the type of adverse drug reaction depending on the category of ICIs</measure>
    <time_frame>Case reported in the World Health Organization (WHO) or BNPV database of individual safety case reports to May 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the other immune related adverse events concomitant to the adverse drug reaction induced by ICIs</measure>
    <time_frame>Case reported in the World Health Organization (WHO) or BNPV database of individual safety case reports to May 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the duration of treatment when the toxicity happens (role of cumulative dose)</measure>
    <time_frame>Case reported in the World Health Organization (WHO) or BNPV database of individual safety case reports to May 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the drug-drug interactions associated with adverse events</measure>
    <time_frame>Case reported in the World Health Organization (WHO) or BNPV database of individual safety case reports to May 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pathologies (cancer) for which the incriminated drugs have been prescribed</measure>
    <time_frame>Case reported in the World Health Organization (WHO) or BNPV database of individual safety case reports to May 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the population of patients having adverse event</measure>
    <time_frame>Case reported in the World Health Organization (WHO) or BNPV database of individual safety case reports to May 2018</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Arthritis</condition>
  <condition>Cancer</condition>
  <condition>Cardiac Disease</condition>
  <condition>Endocrine System Diseases</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Ophthalmopathy</condition>
  <condition>Myositis</condition>
  <condition>Neuropathy</condition>
  <arm_group>
    <arm_group_label>Adverse drug reaction induced by immune checkpoint inhibitors</arm_group_label>
    <description>Case reported in the World Health Organization (WHO) and the Base Nationale de PharmacoVigilance of patient treated by ICI, with a chronology compatible with the drug toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune checkpoint inhibitor</intervention_name>
    <description>Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).</description>
    <arm_group_label>Adverse drug reaction induced by immune checkpoint inhibitors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with an ICI for a cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Case reported in the World Health Organization (WHO) database and Base Nationale de
             Pharmacovigilance (BNPV) of individual safety case reports to 01/05/2018

          -  Adverse events reported

          -  Patients treated with ICIs, in monotherapy or combination, included in the ATC:
             Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab
             (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).

        Exclusion Criteria:

        • Chronology not compatible between the drug and the toxicity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM.</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB. Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist. 2019 May;24(5):584-588. doi: 10.1634/theoncologist.2018-0574. Epub 2019 Feb 28.</citation>
    <PMID>30819785</PMID>
  </reference>
  <reference>
    <citation>Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677.</citation>
    <PMID>31189043</PMID>
  </reference>
  <reference>
    <citation>Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019 May 22;7(1):134. doi: 10.1186/s40425-019-0617-x.</citation>
    <PMID>31118078</PMID>
  </reference>
  <reference>
    <citation>Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM. A case report of clonal EBV-like memory CD4(+) T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019 Aug;25(8):1243-1250. doi: 10.1038/s41591-019-0523-2. Epub 2019 Jul 22.</citation>
    <PMID>31332390</PMID>
  </reference>
  <reference>
    <citation>Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019 Jul 2;140(2):80-91. Review.</citation>
    <PMID>31390169</PMID>
  </reference>
  <results_reference>
    <citation>Arnaud L, Lebrun-Vignes B, Salem JE. Checkpoint inhibitor-associated immune arthritis. Ann Rheum Dis. 2019 Jul;78(7):e68. doi: 10.1136/annrheumdis-2018-213470. Epub 2018 May 3.</citation>
    <PMID>29724725</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.</citation>
    <PMID>30242316</PMID>
  </results_reference>
  <results_reference>
    <citation>Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacol Ther. 2018 Sep;189:89-103. doi: 10.1016/j.pharmthera.2018.04.009. Epub 2018 Apr 24. Review.</citation>
    <PMID>29698683</PMID>
  </results_reference>
  <results_reference>
    <citation>Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC. Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. Diabetes Care. 2018 Dec;41(12):e150-e151. doi: 10.2337/dc18-1465. Epub 2018 Oct 10.</citation>
    <PMID>30305348</PMID>
  </results_reference>
  <results_reference>
    <citation>Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution. Circulation. 2018 Aug 14;138(7):743-745. doi: 10.1161/CIRCULATIONAHA.118.035898.</citation>
    <PMID>30359135</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Joe Elie Salem</investigator_full_name>
    <investigator_title>Assistant director, clinical investigation center Paris Est</investigator_title>
  </responsible_party>
  <keyword>Anti-PD-1</keyword>
  <keyword>Anti-PD-L1</keyword>
  <keyword>Anti-CTLA-4</keyword>
  <keyword>Immune checkpoint inhibitors</keyword>
  <keyword>Immune adverse drug reactions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

